News and Opinion
There are stories relating to obesity breaking around the world every day. The stories below are those where journalists haver sought NOF opnion/quotes or summaries of research on which NOF may have a view. Where possible the source of the stories are identified by the newspaper banner or a URL in red.
NOF Opinion will always be identified in italics.
- Details
-
Published on Tuesday, 09 August 2011
The failure of new obesity drugs to meet USA Federal Drug Administration [FDA] safety demands is preventing new approvals in obesity therapies. This has left Orlistat - and its over-the-counter version, Alli - as the only long-term therapy approved in Europe and the US . The FDA states that more safety evidence must be provided and both Lorquess and Qnexa have challenging paths to approval. It is not all bad news however. Novo Nordisk is now attempting to establish a higher dose of Victoza diabetes drug as a viable weight-loss drug for non-diabetics. Victoza's mechanisim avoids centrally acting side-effects that have been the cause of recent drugs withdrawals. Pivotal trials are scheduled to begin in the Autumn. [source Datamonitor]